Stay updated on Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.

Latest updates to the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated with new clinical trial results, including specific metrics such as the number of participants with adverse events and detailed definitions of progression-free survival and overall survival. Additionally, important dates for results reporting have been added.SummaryDifference21%
- Check43 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check50 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check72 days agoChange DetectedThe website has updated its intervention details, now listing 'Verified 2022-09 by Inge Marie Svane, Herlev Hospital' and providing new contact information for Cathrine L Lorentzen, MD, while removing previous contact details and intervention type.SummaryDifference2%
- Check101 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.